Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

Eli Lilly & Co. (NYSE:LLY)

Paying users zone. Data is hidden behind: .

  • Get 1-month access to Eli Lilly & Co. for $19.99, or

  • get full access to the entire website for at least 3 months from $49.99.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Verified by Visa MasterCard SecureCode American Express SafeKey

This is a one-time payment. There is no automatic renewal.

Enterprise Value to FCFF (EV/FCFF)

Intermediate level


Free Cash Flow to The Firm (FCFF)

Eli Lilly & Co., FCFF calculation

US$ in thousands

Microsoft Excel LibreOffice Calc
12 months ended: Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Net income (loss)
Net noncash charges
Other changes in operating assets and liabilities, net of acquisitions and divestitures
Net cash provided by operating activities
Cash payments for interest on borrowings, net of tax1
Interest costs capitalized, net of tax2
Purchases of property and equipment
Free cash flow to the firm (FCFF)

Based on: 10-K (filing date: 2020-02-19), 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19).

Item Description The company
FCFF Free cash flow to the firm is the cash flow available to the Eli Lilly & Co.’s suppliers of capital after all operating expenses have been paid and necessary investments in working and fixed capital have been made. Eli Lilly & Co.’s FCFF decreased from 2017 to 2018 and from 2018 to 2019.

Interest Paid, Net of Tax

Eli Lilly & Co., interest paid, net of tax calculation

US$ in thousands

Microsoft Excel LibreOffice Calc
12 months ended: Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Effective Income Tax Rate (EITR)
EITR1
Interest Paid, Net of Tax
Cash payments for interest on borrowings, before tax
Less: Cash payments for interest on borrowings, tax2
Cash payments for interest on borrowings, net of tax
Interest Costs Capitalized, Net of Tax
Interest costs capitalized, before tax
Less: Interest costs capitalized, tax3
Interest costs capitalized, net of tax

Based on: 10-K (filing date: 2020-02-19), 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19).

1 See details »

2 2019 Calculation
Cash payments for interest on borrowings, tax = Cash payments for interest on borrowings × EITR
= × =

3 2019 Calculation
Interest costs capitalized, tax = Interest costs capitalized × EITR
= × =


Enterprise Value to FCFF Ratio, Current

Eli Lilly & Co., current EV/FCFF calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Selected Financial Data (US$ in thousands)
Enterprise value (EV)
Free cash flow to the firm (FCFF)
Valuation Ratio
EV/FCFF
Benchmarks
EV/FCFF, Competitors1
Abbott Laboratories
AbbVie Inc.
Amgen Inc.
Biogen Inc.
Bristol-Myers Squibb Co.
Gilead Sciences Inc.
Illumina Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc.
Zoetis Inc.
EV/FCFF, Sector
Pharmaceuticals & Biotechnology
EV/FCFF, Industry
Health Care

Based on: 10-K (filing date: 2020-02-19).

1 Click competitor name to see calculations.

If the company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.
Otherwise, if the company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.


Enterprise Value to FCFF Ratio, Historical

Eli Lilly & Co., historical EV/FCFF calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Selected Financial Data (US$ in thousands)
Enterprise value (EV)1
Free cash flow to the firm (FCFF)2
Valuation Ratio
EV/FCFF3
Benchmarks
EV/FCFF, Competitors4
Abbott Laboratories
AbbVie Inc.
Amgen Inc.
Biogen Inc.
Bristol-Myers Squibb Co.
Gilead Sciences Inc.
Illumina Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc.
Zoetis Inc.
EV/FCFF, Sector
Pharmaceuticals & Biotechnology
EV/FCFF, Industry
Health Care

Based on: 10-K (filing date: 2020-02-19), 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19).

1 See details »

2 See details »

3 2019 Calculation
EV/FCFF = EV ÷ FCFF
= ÷ =

4 Click competitor name to see calculations.

Valuation ratio Description The company
EV/FCFF Enterprise value to free cash flow to the firm is whole company valuation indicator. Eli Lilly & Co.’s EV/FCFF ratio increased from 2017 to 2018 and from 2018 to 2019.